- Home
- RCKT vs KURA Comparison
RCKT vs KURA Comparison
Compare RCKT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- KURA
- Stock Information
- Founded
- RCKT 1999
- KURA 2014
- Country
- RCKT United States
- KURA United States
- Employees
- RCKT N/A
- KURA N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCKT Health Care
- KURA Health Care
- Exchange
- RCKT Nasdaq
- KURA Nasdaq
- Market Cap
- RCKT 1.4B
- KURA 1.3B
- IPO Year
- RCKT N/A
- KURA N/A
- Fundamental
- Price
- RCKT $13.98
- KURA $15.92
- Analyst Decision
- RCKT Strong Buy
- KURA Strong Buy
- Analyst Count
- RCKT 9
- KURA 7
- Target Price
- RCKT $53.22
- KURA $29.83
- AVG Volume (30 Days)
- RCKT 744.0K
- KURA 821.5K
- Earning Date
- RCKT 11-07-2024
- KURA 11-07-2024
- Dividend Yield
- RCKT N/A
- KURA N/A
- EPS Growth
- RCKT N/A
- KURA N/A
- EPS
- RCKT N/A
- KURA N/A
- Revenue
- RCKT N/A
- KURA N/A
- Revenue This Year
- RCKT N/A
- KURA N/A
- Revenue Next Year
- RCKT $411.05
- KURA N/A
- P/E Ratio
- RCKT N/A
- KURA N/A
- Revenue Growth
- RCKT N/A
- KURA N/A
- 52 Week Low
- RCKT $13.80
- KURA $9.06
- 52 Week High
- RCKT $32.53
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- RCKT 27.71
- KURA 34.68
- Support Level
- RCKT $16.65
- KURA $16.55
- Resistance Level
- RCKT $17.83
- KURA $19.73
- Average True Range (ATR)
- RCKT 0.89
- KURA 0.98
- MACD
- RCKT -0.27
- KURA -0.05
- Stochastic Oscillator
- RCKT 4.12
- KURA 8.86
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.